Hidalgo Ramos Roberto A, Hong Isaac, Ortiz Marcelo, Secades Daniela, Dufner Krieger Sebastián, Ramos Stanziola Linet
Faculty of Medicine, University of Costa Rica, San Jose, CRI.
Anesthesiology, Hospital San Francisco de Asis, Grecia, CRI.
Cureus. 2025 Jul 29;17(7):e89020. doi: 10.7759/cureus.89020. eCollection 2025 Jul.
Tirzepatide has become a treatment option for weight management, with increasing interest in its effects on skeletal muscle. This systematic review evaluated the impact of tirzepatide on skeletal muscle mass and lean body composition in adults. A structured search of four major databases was conducted up to June 26, 2025, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. The included studies were randomized clinical trials that assessed skeletal muscle or lean mass using validated imaging methods in adults treated with tirzepatide. The available evidence suggests that treatment is associated with reductions in fat mass while maintaining the relative preservation of lean mass. Indicators of muscle composition remained stable or showed signs of improvement. These findings support the potential of tirzepatide to improve overall body composition without significantly compromising skeletal muscle. Further research is needed to confirm these results and explore their functional significance over time.
替尔泊肽已成为体重管理的一种治疗选择,人们对其对骨骼肌的影响越来越感兴趣。本系统评价评估了替尔泊肽对成年人骨骼肌质量和瘦体成分的影响。按照系统评价和Meta分析的首选报告项目(PRISMA)指南,截至2025年6月26日对四个主要数据库进行了结构化检索。纳入的研究为随机临床试验,这些试验使用经过验证的成像方法评估接受替尔泊肽治疗的成年人的骨骼肌或瘦体重。现有证据表明,治疗与脂肪量减少相关,同时保持瘦体重相对保留。肌肉成分指标保持稳定或显示改善迹象。这些发现支持替尔泊肽在不显著损害骨骼肌的情况下改善整体身体成分的潜力。需要进一步研究来证实这些结果,并随着时间推移探索其功能意义。